Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment
Phase 3
Completed
- Conditions
- HIV Infections
- Interventions
- Drug: DTGDrug: LPV/RTVDrug: Two NRTIs
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 627
- Registration Number
- NCT02227238
- Locations
- πΊπ¦
GSK Investigational Site, Zaporizhzhya, Ukraine
Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 21
- Registration Number
- NCT02206711
- Locations
- πΊπΈ
GSK Investigational Site, Madison, Wisconsin, United States
Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 15
- Registration Number
- NCT02185300
- Locations
- πΊπΈ
GSK Investigational Site, Overland Park, Kansas, United States
Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection
Phase 3
Completed
- Conditions
- Infection, Human Immunodeficiency VirusHIV Infections
- Interventions
- Drug: DTG 50 mgDrug: EFV 600 mg
- First Posted Date
- 2014-07-01
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 113
- Registration Number
- NCT02178592
- Locations
- πΉπ
GSK Investigational Site, Khon Kaen, Thailand
Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 38
- Registration Number
- NCT02164045
- Locations
- πΊπΈ
GSK Investigational Site, San Antonio, Texas, United States
Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects
Phase 1
Completed
- Conditions
- Infections, Human Immunodeficiency Virus and Hepatitis
- Interventions
- First Posted Date
- 2014-06-09
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 20
- Registration Number
- NCT02159131
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Study of Combined Oral Contraceptive Effects in Female Subjects
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Drug: BMS-955176Drug: Ortho Cyclen
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 46
- Registration Number
- NCT02157467
Drug-drug Interaction (DDI) Rifabutin
Phase 1
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 102
- Registration Number
- NCT02138084
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects
Phase 2
Completed
- Conditions
- Infection, Human Immunodeficiency VirusHIV Infections
- Interventions
- Drug: CAB LADrug: CAB Oral TabletsOther: HAARTDrug: ABC/3TC Oral tabletsDrug: RPVDrug: RPV Oral Tablets
- First Posted Date
- 2014-04-22
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 309
- Registration Number
- NCT02120352
- Locations
- πͺπΈ
GSK Investigational Site, Madrid, Spain
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
Phase 3
Completed
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Drug: ABC/DTG/3TC FDCDrug: Ongoing cART regimen
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 555
- Registration Number
- NCT02105987
- Locations
- π΅π·
GSK Investigational Site, San Juan, Puerto Rico
Β© Copyright 2025. All Rights Reserved by MedPath